RecruitingPhase 1NCT07553663

Evaluating the Pharmacokinetics and Safety of Miricorilant

A Phase 1b, Open-Label Study Evaluating the Pharmacokinetics and Safety of Miricorilant in Adult Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Sponsor

Corcept Therapeutics

Enrollment

15 participants

Start Date

Apr 30, 2026

Study Type

INTERVENTIONAL

Conditions

Nonalcoholic Steatohepatitis (NASH)Non-alcoholic Fatty Liver Disease NAFLD Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis Metabolic dysfunction–associated steatotic liver disease (MASLD)

Summary

A Phase 1b, Open-Label Study Evaluating the Pharmacokinetics and Safety of Miricorilant in Adult Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Miricorilant for people with metabolic dysfunction-associated steatohepatitis (mash) / nonalcoholic steatohepatitis (nash) with compensated cirrhosis, metabolic dysfunction–associated steatotic liver disease (masld), and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.